Contineum Therapeutics, trading on NASDAQ under the ticker CTNM, is a clinical-stage biotechnology company focused on the discovery and development of small‐molecule immunomodulators for the treatment of infectious diseases and oncology. Leveraging its proprietary platform, Contineum Therapeutics designs novel compounds that target innate immune receptors to restore or rebalance immune responses. The company’s R&D efforts emphasize precision modulation of toll-like receptors (TLRs) and other pattern recognition receptors, with an eye toward both monotherapy and combination regimens in areas of high unmet need.
At the heart of Contineum’s pipeline is a series of lead candidates each addressing distinct immuno‐regulatory pathways. One such program targets TLR8 to mitigate excessive inflammatory responses in severe bacterial infections, while another focuses on boosting anticancer immunity through dual TLR7/8 activation. Preclinical studies have demonstrated proof of mechanism across multiple indications, and the company is preparing for first‐in‐human trials. Contineum has also established collaborative research partnerships with leading academic institutions and contract research organizations to accelerate translational studies.
Founded in 2021 as a spin‐out from a pharmaceutical innovation incubator, Contineum Therapeutics is headquartered in Scottsdale, Arizona. Since inception, the company has built a multidisciplinary team of immunologists, chemists and clinical development experts. Its state-of-the-art laboratories and manufacturing partnerships support both lead optimization and scalable production, allowing Contineum to advance multiple assets toward the clinic in parallel.
Under the leadership of CEO Scott Davidson, a seasoned executive with over two decades of experience in biopharma, Contineum maintains a governance structure committed to scientific rigor and operational discipline. The company’s board and management team bring expertise in drug discovery, regulatory affairs and commercial strategy, positioning Contineum to address global patient populations in North America, Europe and Asia. As it progresses toward clinical milestones, Contineum continues to seek strategic collaborators and investors to support its mission of delivering next‐generation immunotherapies.
AI Generated. May Contain Errors.
Free CTNM Stock Alerts